Bausch Health Companies Inc. (BHC)
| Market Cap | 2.35B +10.1% |
| Revenue (ttm) | 10.85B +10.1% |
| Net Income | -1.10B |
| EPS | -2.95 |
| Shares Out | 373.99M |
| PE Ratio | n/a |
| Forward PE | 1.50 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,249,217 |
| Open | 6.54 |
| Previous Close | 6.44 |
| Day's Range | 6.14 - 6.54 |
| 52-Week Range | 4.33 - 8.69 |
| Beta | 0.38 |
| Analysts | Hold |
| Price Target | 7.50 (+19.24%) |
| Earnings Date | Jul 29, 2026 |
About BHC
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for BHC stock is "Hold." The 12-month stock price target is $7.5, which is an increase of 19.24% from the latest price.
News
Bausch Health Companies Earnings Call Transcript: Q2 2026
Q2 saw record revenue and adjusted EBITDA growth, with all segments contributing and strong cash flow enabling significant debt reduction. Full-year guidance was raised across all metrics, though H2 growth will moderate due to inventory, generic competition, and Medicaid/340B headwinds.
Bausch Health Companies Earnings release: Q2 2026
Bausch Health Companies released its Q2 2026 earnings on July 29, 2026, summarizing the period's financial results.
Bausch Health Companies Slides: Q2 2026
Bausch Health Companies has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 29, 2026.
Bausch Health Companies Quarterly report: Q2 2026
Bausch Health Companies has published its Q2 2026 quarterly earnings report on July 29, 2026.
Bausch Health reports Q2 non-GAAP EPS $1.26, consensus $1.01
Reports Q2 revenue $2.85B, consensus $2.66B. “Q2 marks our thirteenth consecutive quarter of year-over-year growth in Revenue and Adjusted EBITDA for Bausch Health (BHC), excluding Bausch + Lomb, refl...
BAUSCH HEALTH ANNOUNCES SECOND QUARTER 2026 RESULTS, RAISES GUIDANCE
Second Quarter Consolidated Revenues of $2.85 billion, up 13% on a Reported basis and 11% on an Organic (non-GAAP)1 basis over the prior year period GAAP Net Income Attributable to Bausch Health of $2...
Bausch to stop glaucoma eye drop development after trial miss
Bausch + Lomb said on Thursday its glaucoma eye drop had missed the main goal in a mid-stage trial of replicating visual function improvements observed in a smaller study.
Bausch Health to Announce Second Quarter 2026 Results on July 29, 2026
LAVAL, QC, July 7, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release second quarter 2026 financial results after market close on Wednesday, July 29, 2026. Bausch Healt...
Michael Goettler Resigns from Bausch Health's Board of Directors
LAVAL, QC, July 1, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that Michael Goettler has resigned from its Board of Directors, effective June 30, 2026, in con...
Bausch Health's Aesthetic Business, Solta Medical, Earns Prestigious Trademark Certification of Thermage® in China
Thermage ® , a pioneer in non-invasive skin tightening, was awarded the AAA Well-Known Trademark Certification, the highest recognition in China's domestic trademark evaluation system. LAVAL, QC, May...
Bausch Health Companies Transcript: RBC Capital Markets Global Healthcare Conference 2026
Management highlighted sustained growth across key franchises, strong execution in China and Solta, and a focus on maximizing cash flow through 2027. The company is preparing for post-XIFAXAN transition, managing legal risks, and considering options to monetize its BLCO stake.
Bausch Health Announces 2026 Annual Meeting of Shareholder Results
LAVAL, QC, May 19, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that shareholders elected all 10 director nominees at its 2026 Annual Meeting of Shareholders (...
Bausch Health Companies Transcript: Barclays 30th Annual Leveraged Finance Conference 2026
Twelve consecutive quarters of growth were driven by strong Salix and Solta performance, with AI-powered strategies sustaining XIFAXAN's momentum. Liquidity is robust, with plans to monetize B&L shares post-2028, and guidance incorporates regulatory and global risks.
Bausch Health Companies Transcript: AGM 2026
The meeting confirmed quorum, introduced ten director nominees, and presented three voting items: director elections, executive compensation, and auditor appointment. All proposals passed by majority vote, and no shareholder questions were received.
Bausch + Lomb Launches PreserVision AREDS3™ Eye Vitamins in the United States
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launc...
Bausch Health to Participate in RBC Capital Markets 2026 Global Healthcare Conference
LAVAL, QC, May 13, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that Thomas J. Appio, Chief Executive Officer, and Jean-Jacques Charhon, Executive Vice Preside...
Bausch Health to Participate in Barclays 30th Annual Leveraged Finance Conference
LAVAL, QC, May 12, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that members of company management will participate in a fireside chat at the Barclays 30th Ann...
Bausch + Lomb Launches Bi-Blade+™ Dual-Port Vitrectomy Cutter in Europe
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the European l...
Bausch Health Companies Earnings Call Transcript: Q1 2026
Revenue and adjusted EBITDA grew double digits year-over-year, led by Salix and Solta, with strong cash flow and reduced net debt. Guidance for 2026 is reaffirmed, including minimal expected tariff impact, and AI-driven initiatives are boosting commercial and R&D productivity.
Bausch Health Companies Slides: Q1 2026
Bausch Health Companies has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 29, 2026.
Bausch Health Companies Earnings release: Q1 2026
Bausch Health Companies released its Q1 2026 earnings on April 29, 2026, summarizing the period's financial results.
Bausch Health Companies Quarterly report: Q1 2026
Bausch Health Companies has published its Q1 2026 quarterly earnings report on April 29, 2026.
Bausch Health reports Q1 non-GAAP EPS 78c, consensus 69c
Reports Q1 revenue $2.52B, consensus $2.41B. “Our Q1 performance marks twelve consecutive periods of year-over-year growth in revenue, adjusted EBITDA for Bausch Health (BHC) excluding Bausch + Lomb, ...
Bausch Health sees 2026 revenue $10.67B-$10.92B, consensus $10.68B
16:17 EDT Bausch Health (BHC) sees 2026 revenue $10.67B-$10.92B, consensus $10.68B
BAUSCH HEALTH ANNOUNCES FIRST QUARTER 2026 RESULTS
First Quarter Consolidated Revenues of $2.52 billion, up 12% on a Reported basis and 7% on an Organic (non-GAAP)1 basis over the prior year period GAAP Net Loss Attributable to Bausch Health of $1,423...